What is the current price and trading status of ADXN.SW stock?

ADXN.SW stock trades on SIX at **CHF 0.0466** as of the pre-market update on 18 Mar 2026. The session showed a **5.91%** rise with **16,384** shares traded. Liquidity is low versus the 50-day average volume.

What forecasts and price targets exist for ADXN.SW stock?

Meyka AI's forecast model projects a quarterly target of **CHF 0.05**, a monthly target of **CHF 0.03**, and a 12-month projection of **CHF 0.031642**. These model-based figures imply short-term upside but longer-term downside risk.

How does Meyka grade ADXN.SW and what does it mean?

Meyka AI gives ADXN.SW a **score of 66.83 (Grade B)** with a **HOLD** suggestion. The grade factors in benchmark comparison, sector and industry data, financial growth, key metrics, and analyst inputs. This is informational, not advice.

What are the main risks for ADXN.SW stock investors?

Principal risks include development-stage cash burn, trial outcomes, limited liquidity, large share count, and biotech sector volatility. Price can gap on news. Use small position sizes and event-driven risk controls.

CH Stocks

ADXN.SW Addex Therapeutics (SIX) up 5.91% pre-market 18 Mar 2026: watch catalysts and liquidity

ByDanny Kontos March 18, 2026

Pre-market trading flags ADXN.SW stock after a 5.91% uptick to CHF 0.0466 on 18 Mar 2026. Addex Therapeutics Ltd (ADXN.SW) on the SIX market hit a day high of CHF 0.0466 with volume at 16,384 shares. We look at what moved the price, how valuation and technicals line up, and what traders should watch ahead of the company’s next earnings and pipeline catalysts. This Meyka AI-powered market analysis platform note frames short-term trade setups and the longer term forecast.